Cognitive and Brain Aging: Using Imaging to Distinguish Potential Risks and Benefits of Estrogen

Susan M. Resnick, PhD Laboratory of Personality and Cognition National Institute on Aging





CONTEXT: Estrogen-Containing HT Effects on Specific Cognitive Functions

- Age-related changes are observed in some but not all cognitive functions.
- Estrogens and other hormones may have different effects on specific aspects of cognitive functions.

Baltimore Longitudinal Study of Aging BLSA

- Study initiated in 1958
- Women studied since 1978
- Highly educated community-dwelling sample
- NIA-IRP visits every 2 years for 2 1/2 days
- Behavioral and physical assessments
- Prospective diagnoses of dementia

Benton Visual Retention Test



HT Users Have Better Figural Memory and Fewer Errors Over Time



Resnick et al. Neurology 1997

HT is Associated with Better Verbal Learning and Memory



(* p < .05, ** p < .01)

Maki, Zonderman & Resnick. Am J Psychiatry 2001

HT Users Have Greater Longitudinal Increases in Hippocampal CBF over a 2-Year Interval



Randomized Trials in the WHI: Estrogen (CEE) Alone and Combination CEE + MPA



WHI
40 sites
N = 27,348

WHIMS 39 sites N = 7480 WHISCA 14 sites N = 2302

WHISCA: Women's Health Initiative Study of Cognitive Aging

- Effects of CEE alone and combination CEE + MPA assessed within the framework of a largescale clinical trial
- Longitudinal assessments to evaluate withinindividual change
- Emphasis on tests with demonstrated sensitivity to:
 - --Age effects
 - --Hormone effects
 - --A broad range of performance

WHISCA Test Battery

Cognitive Function

Word Knowledge Verbal Fluency Figural Memory Verbal Memory Attention and Working Memory Spatial Ability Motor Speed Affect

Test

PMA Vocabulary Letter and Category Fluency Benton Visual Retention Test BVRT California Verbal Learning Test CVLT

Digits Forward and Backward Card Rotations

Finger Tapping

PANAS Positive and Negative Affect Geriatric Depression Scale GDS

CEE + MPA Subtrial (N = 1416) Sample Characteristics of WHISCA

	Placebo (726)	E + P (690)
e at WHISCA rollment (yrs)	73.86 (3.8)	73.69 (3.6)
ne from WHI ndomization	3.0 (0.7)	3.0 (0.7)
low-up period (yrs)	1.36 (0.6)	1.33 (0.6)
ucation <u>></u> college grad)	34.5	36.0
ce (n, %white)	673 (93.0)	632 (91.6)
II baseline 3MS	96.15 (3.6)	96.24 (3.5)

68

68

% of Eligible Women

Ag

En

Tin

Ra

Fo

Ed

(%

Ra

WH

WHISCA assessments completed prior to termination of study medications on July 8, 2002 CEE + MPA Placebo Ν Ν Initial Assessment 726 690 **One-year follow-up** 673 (92.7%) 636 (92.2%) 320 (44.1%) 291 (42.2%) **Two-year follow-up**

WHISCA Initial Assessment: CEE + MPA Effects on Specific Cognitive Functions



* p <u><</u> 0.05

Annual Rates of Change: CEE + MPA Effects on Specific Cognitive Functions

Tapping Nondom Tapping Dom Card Rotations Digits Backward Digits Forward CVLT Delay CVLT Imm BVRT Category Fluency Letter Fluency Vocabulary



* p <u><</u> 0.05; ** p <u><</u> 0.01

WHISCA CONCLUSIONS

- Combination HT may have different effects on different cognitive functions.
- These effects are modest and are seen only after 4 to 5 years of treatment.
- Our understanding of the effects of HT on cognitive function is still evolving.

WHIMS/WHISCA vs. BLSA Studies

- Age: WHISCA women 7-10 years older than BLSA women
- Timing of Initiation of HT: Most BLSA women began HT during or shortly after menopause
- Duration of treatment: More than 40% of BLSA women used HT for 5 or more years
- Regimen: Variety of treatments in BLSA, with higher likelihood of E alone and cyclical E/P treatments

Reconciling WHIMS and WHISCA E + P Findings: Competing Risks and Cognition

SPECIFIC COGNITION FUNCTIONS

Increased Risk for Stroke and Thromboembolic Events

MPA Antagonizes Beneficial Effects of E on CNS Protect Against Development of AD Pathology in Healthy Women

Directions

- WHISCA CEE alone analysis continuing
- Continued follow-ups to assess long-term effects of HT in older women
- WHIMS MRI substudy to investigate joint effects of infarcts and atrophy on cognitive change
- Imaging to distinguish potential risks from benefits
 Atrophy, vascular, and inflammatory changes with MRI
 Blood flow and metabolism with PET and MRI
 In vivo amyloid burden with PET

WHISCA – NIA R & D Contract N01-AG-1-2106

<u>NIA</u>

Susan Resnick, PhD Pauline Maki, PhD Alan Zonderman, PhD

Wake Forest University

Sally Shumaker, PhD Stephen Rapp, PhD Mark Espeland, PhD Laura Coker, PhD

WHISCA Sites

Gainesville Milwaukee **Minneapolis New York City** Rush Presbyterian-St. Lukes MC **Ohio State University Stanford University State University of New York-Stony** Brook **University of California-Davis** University of California–LA University of Iowa College of Medicine **University of Massachusetts-Worcester University of Nevada University of North Carolina**

E + P is Associated with Decreases in BVRT Errors over Time



- Observed treatment effect of 0.27 errors per year vs. predicted treatment effect of 0.23 errors per year
- BVRT errors predict AD years prior to diagnosis

E + P is Associated with Greater Declines in CVLT Verbal Memory at Visit 3



WHISCA Diagnoses During Follow-up

- 11 cases of probable dementia (5 E + P, 6 Placebo)
- 19 cases of mild cognitive impairment (6 E + P, 13 Placebo)
- 14 incident strokes (9 E + P, 5 Placebo)

No Effect of E + P on Affect at WHISCA Enrollment or Rates of Change

Measure

Affect PANAS Positive PANAS Negative GDS Differences (E+P – PL) at WHISCA Enrollment

> 0.02 (0.03) 0.01 (0.03) -0.03 (0.11)

Differences (E+P – PL) in Rates of Change

> 0.01 (0.02) -0.02 (0.02) 0.04 (0.07)

Group Differences at WHISCA Enrollment and in Rates of Change (Intention-to-treat)

Measure	Differences (E+P – PL) at WHISCA Enrollment	Differences (E+P – PL) in Rates of Change
<i>Verbal Knowledge</i> PMA Vocabulary	-0.35 (0.51)	-0.10 (0.17)
Verbal Fluency		
Letter Fluency	0.23 (0.66)	-0.28 (0.29)
Category Fluency	-0.14 (0.33)	-0.09 (0.19)
Figural Memory		
BVRT	0.11 (0.20)	-0.27 (0.11)**
Verbal Memory		
CVLT Free	0.23 (0.34)	-0.52 (0.20)**
CVLT Delay	0.15 (0.16)	-0.23 (0.10)*

**p <u>< 0.01;</u> * p <u>< 0.05</u>

Group Differences at WHISCA Enrollment and in Rates of Change

Measure	Differences (E+P – PL)	Differences (E+P – PL
Attention and		III Rales of Change
Working Memory		
Digits Forward	-0.22 (0.11)*	0.06 (0.06)
Digits Backward	-0.19 (0.11)	0.08 (0.06)
Spatial Ability		
Card Rotations	1.07 (1.44)	-0.39 (0.70)
Motor Speed		
Finger Tapping – Dom	0.10 (0.42)	0.00 (0.21)
Finger Tapping – Non	0.11 (0.35)	0.02 (0.17)
Affect		
PANAS Positive	0.02 (0.03)	0.01 (0.02)
PANAS Negative	0.01 (0.03)	-0.02 (0.02)
GDS	-0.03 (0.11)	0.04 (0.07)